Who can use Filspari(Sparsentan)?
Sparsentan is an oral dual endothelin-angiotensin receptor antagonist (DEARA) developed by Travere Therapeutics, Inc. in the United States.
Who can use Filspari(Sparsentan)?
The drug received accelerated approval from the U.S. Food and Drug Administration (FDA) in February 2023 and conditional marketing authorization from the European Union in April 2024.
FILSPARI is indicated to reduce proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression, typically with a urine protein-to-creatinine ratio (UPCR) of ≥1.5 g/g.
